Trialbee Announces Release of HIVE
Trialbee has announced the release of HIVE, a smart data science application applied on Real World Data aiming to enhance targeting and precision in performance-driven patient recruitment for global clinical trials.
“Traditional patient recruitment has limited access to patients and takes a long time to accomplish. Digital advertising for clinical trials, to supplement the pool of patients available to investigators, often results in large burdensome screening activities for the sites only to result in a few additional patients to enroll. Trialbee HIVE uses a smart modeling technique and expands the pool of potential clinical trial participants and then narrows down the pool to only the most relevant candidates matching the study criteria,” said Lollo Eriksson, Chief Strategy Officer at Trialbee.
For more information, click here.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
